⁃ A subject will be eligible for study participation if he/she meets the following criteria within 21 days prior to randomization.

• Subject must have confirmation of previously untreated AML by World Health Organization (WHO) criteria, and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities. Prior therapy with hydroxyurea or a total dose of cytarabine no more than 0.5g (for emergency use for stabilization) is allowed.

• Subject must be≥18 years of age with at least one of the following conditions:

• A)≥60 years of age; B) Patients aged \< 60 years who are unsuitable for standard induction therapy（Any other comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy); C) The patient refused the conventional intensive chemotherapy.

• Adequate organ function as defined below:

• A)liver function (bilirubin≤2mg/dL, aspartate transaminase (AST) and/or alanine transaminase (ALT)≤3 x ULN).

• Unless liver enzyme abnormalities are determined by the treating MD and PI to be due to leukemic infiltration.

• B)kidney function (creatinine≤1.5xULN ).

• ECOG performance status of ≤ 2.

• A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.

• Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol.

• Patient must have a projected life expectancy of at least 12 weeks.